| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Kyoto, 606-8507 Japan [F. T., S. I., K. Y., R. M., Y. K., M. L., H. W.], and Department of Thoracic Surgery, Seishin-Iryo Center Hospital, Kobe 651-2273, Japan [Y. O.]
Angiopoietin (Ang)-1 and -2 have been recently identified as potent angiogenic factors which function in concert with vascular endothelial growth factor (VEGF), but no detailed clinical study on Ang expression has been reported. To assess the clinical significance of Ang expression in non-small cell lung cancer (NSCLC), a total of 236 patients with pathological stage-I-IIIA disease were retrospectively reviewed. Expression of Ang-1, Ang-2, or VEGF was examined immunohistochemically; intratumoral microvessel density (IMVD) was examined with immunohistochemical staining against CD34, a marker of pan-endothelial cells (CD34-IMVD), and that against CD105, a marker of proliferative endothelial cells (CD105-IMVD). Positive expression of Ang-1 and that of Ang-2 were seen in 101 (42.8%) and 40 patients (16.9%), respectively. There was no significant correlation between Ang-1 expression and CD34-IMVD or CD105-IMVD. In contrast, the average CD105-IMVD for Ang-2-positive tumor was significantly higher than that for Ang-2-negative tumor (56.7 versus 38.5; P = 0.032). More interestingly, such an angiogenic effect of Ang-2 was seen only when VEGF expression was high; when VEGF expression was high, the average CD105-IMVD for Ang-2-positive tumor was significantly higher than that for Ang-2-negative tumor (89.1 versus 63.6; P = 0.045); when VEGF expression was low, the average CD105-IMVD for Ang-2-positive tumor and that for Ang-2-negative tumor were almost the same (27.4 and 27.1, respectively). Moreover, positive expression of Ang-2, not Ang-1, was a significant factor to predict a poor postoperative survival (5-year survival rates for Ang-2-positive patients and -negative patients were 53.5 and 70.3%, respectively; P = 0.027), which was confirmed by a multivariate analysis. The influence of Ang-2 status on postoperative survival was enhanced when VEGF expression was high. That said, the 5-year survival of Ang-2-positive and VEGF-high patients was extremely low (41.4%) as compared with that for Ang-2-negative and VEGF-low patients (66.6%), as compared with that for Ang-2-positive and VEGF-low patients (63.6%), and as compared with that for Ang-2-negative and VEGF-low patients (71.8%). In conclusion, positive Ang-2 expression was significantly correlated with a poor prognosis, as well as with aggressive angiogenesis in resected NSCLC that was enhanced in the presence of high VEGF expression.
This article has been cited by other articles:
|
|
 |
|
  M. Szymczak, M. Murray, and N. Petrovic Modulation of angiogenesis by {omega}-3 polyunsaturated fatty acids is mediated by cyclooxygenases Blood, April 1, 2008; 111(7): 3514 - 3521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sardari Nia, C. Colpaert, P. Vermeulen, J. Weyler, F. Pezzella, P. Van Schil, and E. Van Marck Different Growth Patterns of Non-Small Cell Lung Cancer Represent Distinct Biologic Subtypes Ann. Thorac. Surg., February 1, 2008; 85(2): 395 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S.N. Shim, I. A.W. Ho, and P. E.H. Wong Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis Mol. Cancer Res., July 1, 2007; 5(7): 655 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Park, K. J. Park, Y. S. Kim, S. S. Sheen, K. S. Lee, H. N. Lee, Y. J. Oh, and S. C. Hwang Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer Chest, July 1, 2007; 132(1): 200 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Abu El-Asrar, L. Missotten, and K. Geboes Expression of hypoxia-inducible factor-1{alpha} and the protein products of its target genes in diabetic fibrovascular epiretinal membranes Br J Ophthalmol, June 1, 2007; 91(6): 822 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Imanishi, B. Hu, M. J. Jarzynka, P. Guo, E. Elishaev, I. Bar-Joseph, and S.-Y. Cheng Angiopoietin-2 Stimulates Breast Cancer Metastasis through the {alpha}5{beta}1 Integrin-Mediated Pathway Cancer Res., May 1, 2007; 67(9): 4254 - 4263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cao, P. Sonveaux, S. Liu, Y. Zhao, J. Mi, B. M. Clary, C.-Y. Li, C. D. Kontos, and M. W. Dewhirst Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth Cancer Res., April 15, 2007; 67(8): 3835 - 3844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Niu and W. B. Carter Human Epidermal Growth Factor Receptor 2 Regulates Angiopoietin-2 Expression in Breast Cancer via AKT and Mitogen-Activated Protein Kinase Pathways Cancer Res., February 15, 2007; 67(4): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Numasaki, M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. Hishinuma, J. Goto, M. T. Lotze, J. K. Kolls, et al. IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis J. Immunol., November 1, 2005; 175(9): 6177 - 6189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhu, C. Lee, F. Shen, R. Du, W. L. Young, and G.-Y. Yang Angiopoietin-2 Facilitates Vascular Endothelial Growth Factor-Induced Angiogenesis in the Mature Mouse Brain Stroke, July 1, 2005; 36(7): 1533 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Rosen VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances Oncologist, June 1, 2005; 10(6): 382 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Loges, G. Heil, M. Bruweleit, V. Schoder, M. Butzal, U. Fischer, U. M. Gehling, G. Schuch, D. K. Hossfeld, and W. Fiedler Analysis of Concerted Expression of Angiogenic Growth Factors in Acute Myeloid Leukemia: Expression of Angiopoietin-2 Represents an Independent Prognostic Factor for Overall Survival J. Clin. Oncol., February 20, 2005; 23(6): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ishikawa, K. Takenaka, K. Yanagihara, R. Miyahara, Y. Kawano, Y. Otake, S. Hasegawa, H. Wada, and F. Tanaka Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non-Small-Cell Lung Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6579 - 6585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-X. Chen, Y. Chen, L. DeBusk, W. Lin, and P. C. Lin Dual functional roles of Tie-2/angiopoietin in TNF-{alpha}-mediated angiogenesis Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H187 - H195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takeuchi, A. Fujimoto, M. Tanaka, T. Yamano, E. Hsueh, and D. S. B. Hoon CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2351 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Chong, G. J. Caine, B. Freestone, A. D. Blann, and G. Y. H. Lip Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure J. Am. Coll. Cardiol., February 4, 2004; 43(3): 423 - 428. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
